First Biologic Targeting TSLP Approved For Severe Asthma
The FDA recently authorized Tezspire as the first asthma treatment targeting thymic stromal lymphopoietin (TSPL), a molecule involved in airway inflammation. While only 5% to 10% of asthma patients meet the criteria for severe asthma, more than 80% of total asthma healthcare costs can be...